drugset / Trial / NCT00153933
Bortezomib in Combination With CC-5013 in Patients With Relapsed/Refractory Multiple Myeloma
Phase 1
Completed
58 enrolled
Dana-Farber Cancer Institute
Beth Israel Deaconess Medical Center · collabBrigham and Women's Hospital · collabH. Lee Moffitt Cancer Center and Research Institute · collab
NaSingle-groupOpen-labelTreatment
Summary
The purpose if this study is to evaluate the side effects of the combination of bortezomib and Revlimid (CC-5013) in patients with relapsed and relapsed/refractory multiple myeloma.
Timeline
- Start
- 2004-08
- Primary completion
- 2014-07
- Completion
- 2014-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bortezomib | Small molecule | — | Intravenous |
| Subject | Lenalidomide | Other / unclassified | — | Oral |